Human Papillomavirus (HPV) vaccine protects against infections with HPV, which is a group of over 200 related viruses, of which over 40 are transmitted by direct sexual contact. Amongst these, two HPV forms cause genital lumps and some other HPV types result in cancers, such as anal, cervical, penile, oropharyngeal, vulvar, and vaginal. Similar to other vaccines that protect against viral infections, HPV vaccines help the body to develop antibodies that can fight against HPV and protect other cells in the body from getting infected.
Genital HPV infection is the most common sexually transmitted infection and is detected in nearly 9–13% of the world’s population and about 6 million people are being infected every year. During adolescence or young adulthood the chances of getting infected by HPV are usually high. HPV infection is deliberated to contribute to nearly 100% cervical cancers, about 80% of anal, and 40–60% of vaginal, penile, and vulvar cancers. Presently, two prophylactic HPV vaccines are commercially obtainable and both are developed from purified L1 structural proteins. Increasing cases of HPV diseases among the population worldwide is boosting the growth of the global human papillomavirus vaccine market.
Why are HPV Vaccines in High Demand?
As per the Centers for Disease Control and Prevention (CDC), HPV is the most commonly occurring sexually transmitted infection in the United States and is associated with health problems including genital warts and cancers. The World Health Organization (WHO) advices to immunize girls in the age group of 9 to 14 years with HPV vaccine, when most of them are not indulged in any sexual activity, to prevent them from getting infected with HPV.
Growing awareness among people about HPV infections and rising cases of HPV diseases in oropharynx, anal, and genital areas across the globe are the major factors boosting the demand for HPV vaccines, thereby driving the growth of the human papillomavirus vaccine market. In addition, governments as well as private institutions are taking up several initiatives for ensuring the availability of the HPV vaccines in order to curb the spread of the virus.
How has the COVID-19 Pandemic Impacted the Human Papillomavirus Vaccine Market?
With the outburst of COVID-19 pandemic the demand for HPV vaccines has surged, thus making a positive impact on the human papillomavirus vaccine industry. According to a research report by Research Dive, the global human papillomavirus vaccine market is anticipated to garner a revenue of $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030. During the pandemic, governments of many regions imposed strict lockdown and implemented several rules to curb the spread of the deadly COVID-19 disease. However, regardless of lockdown restrictions and strict government regulations, the number of COVID-19 infected patients was rising and also most of the healthcare workers were required to perform their duties by risking their lives. Hence, this gave rise to an urgent need to develop effective vaccine, due to which various HPV vaccine manufacturing pharmaceutical companies started investing heavily in research and development of the coronavirus vaccine along with HPV vaccine.
Recent Developments and Key Facts of the Human Papillomavirus Vaccine Market
According to a novel study published in Acta Obstetricia et Gynecologica Scandinavica, a peer-reviewed medical journal covering gynecology, female urology, gynecologic oncology and fertility, HPV vaccine can decrease the chance of high-grade cervical intraepithelial neoplasis (CIN), a condition that can cause cervical cancer.
In addition, in November 2020, the World Health Organization (WHO) has launched a ‘Cervical Cancer Elimination Strategy’ for encouraging all nations to team up and accelerate the elimination of disease with its 3 pronged strategy - 70% screening coverage, 90% HPV vaccine coverage, and 90% access to cervical pre-cancer and cancer treatment.
The key players operating in the global human papillomavirus vaccine market include GlaxoSmithKline Plc, Merck & Co., Inc., Johnson & Johnson, AstraZeneca Plc, Novartis AG, Sanofi S.A., Serum Institute of India Pvt. Ltd., Inovio Pharmaceuticals, Inc., Bharat Biotech, and Xenetic Biosciences, Inc. Besides, several researchers and vaccine manufacturers of the human papillomavirus vaccine market have been taking various initiatives, such as novel developments and researches, strategic partnerships, collaborations, and much more for developing vaccines for HPV. For instance:
- In January 2021, Pregna International Ltd., a leading contraceptive solutions organization, has upgraded its status as a foremost women’s healthcare organization by launching an innovative device which is a cryotherapy device named as CryoPop for fighting cervical cancer.
- In June 2020, Merck known as MSD, a pharmaceutical company, has declared that the U.S. FDA (Food and Drug Administration) has granted approval for an extended indication for GARDASIL 9 for preventing the occurrence of oropharyngeal and other head & neck cancers triggered by HPV types 58, 52, 45, 33, 31, 18, and 16.
Also, researchers are currently studying whether a single dose of HPV vaccine can be effective. A randomized clinical trial is in progress in Costa Rica to examine if a single dose of HPV vaccine is adequate to safeguard against HPV infection.
Future Scope of the Human Papillomavirus Vaccine Industry
As the awareness about prevention of HPV infections is rising, the demand for HPV vaccination is also surging, which is boosting the growth of the global human papillomavirus vaccine market. In addition, growing research & development activities for developing effective HPV vaccines is triggering the industry’s growth. As a final point, the global human papillomavirus vaccine market is soon going to reach newer heights with the development of more efficient vaccines to safeguard the world from human papillomavirus.
Geographically, the North America human papillomavirus vaccine market is estimated to create massive opportunities in the projected timeframe, mainly due to the initiatives taken by government for treating HPV infected people with the human papilloma virus is predicted to be the major driving factor for the region market in the estimated period. For example, in January 2021, the U.S. Department of Health and Human Services (HHS), Office on Women’s Health, and Office of the Assistant Secretary for Health (OASH), launched the HPV VAX NOW campaign with the long-term goal of increasing the rate of human papillomavirus (HPV) vaccination among young adults aged 18 to 26. Besides, the U.S. is projected to have the largest HPV vaccine market owing to its stronger healthcare infrastructure, which is predicted to fortify the growth of the human papillomavirus vaccine market in the near future.